MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:QNTM)

5.600 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.600
Bid (Size) 5.350 (100)
Ask (Size) 6.030 (100)
Prev. Close 5.600
Today's Range 5.600 - 5.600
52wk Range 2.850 - 52.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire

Performance

YTD
-42.9%
-42.9%
1 Month
+14.3%
+14.3%
3 Month
-44.0%
-44.0%
6 Month
-77.4%
-77.4%
1 Year
-44.0%
-44.0%

More News

Read More
News headline image
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Completes 180-Day Toxicity Studies for Lucid-MS
Via Investor Brand Network
News headline image
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)
From Quantum BioPharma
Via GlobeNewswire
News headline image
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Via ACCESS Newswire
News headline image
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
From Quantum BioPharma
Via GlobeNewswire
News headline image
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlighted in CTV W5 Part 2 Covering Alleged Market Manipulation
Via Investor Brand Network
Topics Law Enforcement Lawsuit
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in CTV News W5 Series on Stock Manipulation Allegations
Via Investor Brand Network
Topics Lawsuit
News headline image
Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC
From Quantum BioPharma
Via GlobeNewswire
News headline image
REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
From Quantum BioPharma
Via GlobeNewswire
News headline image
Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in CTV W5 Investigation on Alleged Stock Manipulation
Via Investor Brand Network
Topics Law Enforcement Lawsuit
News headline image
Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern’ Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Announces Private Placement of Class A Multiple Voting Shares
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Licensee Unbuzzd Wellness to Host Investor Webinar Oct. 30
Via Investor Brand Network
News headline image
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication
From Quantum BioPharma
Via GlobeNewswire
TinyGemsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Announces Expiration of Final Hedge Fund Warrants and Confirms Oct. 27 CVR Record Date
Via Investor Brand Network
News headline image
Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend
From Quantum BioPharma
Via GlobeNewswire

Frequently Asked Questions

Is QNTM publicly traded?
Yes, QNTM is publicly traded.
What exchange does QNTM trade on?
QNTM trades on the Canadian Securities Exchange
What is the ticker symbol for QNTM?
The ticker symbol for QNTM is QNTM on the Canadian Securities Exchange
What is the current price of QNTM?
The current price of QNTM is 5.600
When was QNTM last traded?
The last trade of QNTM was at 04/02/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story